Please assess the completion status of the following clinical trial:

Trial Title: Flexitouch Compression System for Venous Stasis Ulcer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* This study will enroll patients in a prospective manner with chronic venous insufficiency and venous stasis ulceration as determined from clinical presentation, positive venous reflux testing, or both.~* Patients must be 18 years old or more.~* The VSU size must be in the range 1-64 cm2.~* The ulcer must extend through both the epidermis and dermis, with no exposed tendon or bone.~* The VSU must have been present for more than 1 month.~* The ulcer must be located between and including the knee and ankle.~* The wound bed must have viable tissues with granulation tissue.~Exclusion Criteria:~* Exposed bone, tendon, or fascia.~* Severe rheumatoid arthritis.~* History of radiotherapy to the ulcer site.~* Uncontrolled congestive heart failure.~* Receiving corticosteroids or immune suppressives.~* History of collagen vascular disease.~* Known malnutrition (albumin \< 2.5 g/dL). If malnutrition is suspected by the principal investigator, the albumin level should be checked to determine whether the patient meets the albumin criterion.~* Ulcer clinically infected at the time of entry into the study. However, patients may be entered into the study after successful treatment of infection.~* Known uncontrolled diabetes (HgbA1c \> 12%). If the principal investigator suspects uncontrolled diabetes, the Hgb A1c should be checked to determine patient eligibility.~* Signs of cellulitis, osteomyelitis, or necrotic or avascular ulcer bed(s).~* Known arterial insufficiency (Ankle-brachial index \< 0.7, or TCPO2 \< 35 mmHg, or Toe brachial index \< 0.4). If the principal investigator suspects uncontrolled diabetes, the Ankle-brachial index should be checked to determine patient eligibility.~* Active sickle cell disease.~* Unable to comply with the procedures described in the protocol.~* Enrolled in a clinical evaluation for another investigational wound-care device or drug.~* Patients diagnosed with deep venous thrombosis or phlebitis in the affected limb in the last 6 months.~* Pregnancy, suspected or confirmed.~* History of peripheral vascular disease, or chronic renal disease.~* Known active or recurrent cancer, or currently receiving chemotherapy or radiation therapy.~* History of pulmonary embolism.~* Poorly controlled asthma.~* Use of Apligraf, skin graft or similar biological dressing within 30 days of study entry.~* Patients with concurrent atrophie blanche.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Standard compression (Type: ACTIVE_COMPARATOR): Patients in this arm will receive current standard of care (once-weekly short-stretch compression wrapping).
- Flexitouch (Type: EXPERIMENTAL): Patients in this arm will receive once-a-week short stretch compression wrapping AND once-daily Flexitouch pump application (including Flexitouch application once-a-week in the clinic setting).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues